
A first-in-human Food and Drug Administration (FDA)–regulated phase 1 safety study of subcutaneous infiltration of sodium channel blocker Neosaxitoxin (NeoSTX) with bupivacaine produced long-lasting anesthesia but no serious adverse events, according to a study in Anesthesiology.









































































